« Return to News | Awards & Advancement

James Cassidy joins Roche

Wednesday, June 29, 2011 12:37 PM

Roche has named James (Jim) Cassidy, M.D., Ph.D., head of translational medicine in the oncology discovery and translational area (DTA) in pharma research and early development (pRED).

A British native, Jim was Professor of Oncology, head of the Department of Cancer Research and head of the Division of Cancer Sciences and Molecular Pathology at the University of Glasgow, Scotland. His major research interests include Telomerase, DNA repair, drug resistance and molecular pharmacology of anti-cancer drugs.

Previously, he was the first Professor of Oncology at Aberdeen University in the U.K., where he developed both an academic unit of clinical oncology and a laboratory-based cancer research group. 

Jim chairs the West of Scotland Cancer Research Network and is a member of Cancer Research U.K., the American Society of Clinical Oncology, the American and British Associations for Cancer Research, the Association of Cancer Physicians and the National Cancer Research Institute.  He is also a Fellow of the Royal Society of Edinburgh.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.